JIBI INKOKA TEMBO
Online ISSN : 1883-6429
Print ISSN : 0386-9687
ISSN-L : 0386-9687
Volume 56, Issue 1
Displaying 1-7 of 7 articles from this issue
FEATURE ARTICLE
ORIGINAL PAPERS
  • Jiro Iimura, Atsushi Hatano, Yasushi Shigeta, Matsusato Tsuyumu, Yuji ...
    2013 Volume 56 Issue 1 Pages 14-19
    Published: February 15, 2013
    Released on J-STAGE: February 15, 2014
    JOURNAL FREE ACCESS
    Epistaxis is one of the most common ENT emergencies. As a treatment policy, the arrest-of-hemorrhage method also changes with various factors, such as age, the bleeding point, and the cause of bleeding. We set the period of one year and classified the cause of bleeding. The subjects were 346 patients in whom an emergency consultation was performed with epistaxis as the chief complaint. The results revealed that tumorous bleeding accounted for 1.7%. We therefore suggest that tumors are a disease which must not be overlooked, and the rate of 1.7% is by no means so small. When treating a case of epistaxis, it is necessary to keep tumorous bleeding in mind and to treat it carefully. When a tumor is suspected as the source of the bleeding, a pathological inspection should be positively conducted.
    Download PDF (1581K)
  • Yutaro Ida
    2013 Volume 56 Issue 1 Pages 20-24
    Published: February 15, 2013
    Released on J-STAGE: February 15, 2014
    JOURNAL FREE ACCESS
    Sarcoidosis is a systemic granulomatous disease of unidentified cause, most commonly affecting the lungs, heart, eyes and skin; neurologic involvement is seen in approximately 5% of cases.
    Neurologic involvement in sarcoidosis could affect the brain parenchyma, meninges, or indeed any other site of the central nervous system; however, cranial nerve involvement is the most site of neurologic involvement.
    The most frequently affected cranial nerve in neurologic sarcoidosis is the facial nerve, with 40~60% of cases manifesting facial paralysis.
    We encountered a case of sarcoidosis in which facial paralysis was the presenting symptom.
    It is important to rule out intracranial lesions or neuromuscular disorders as the cause in patients presenting with facial paralysis, and evaluation by chest X-ray, electrocardiography, brain MRI is important with the findings such as the shifted strain of the forehead constantly.
    Download PDF (772K)
  • Sayuri Kaida, Takashi Iino, Hiromi Kojima
    2013 Volume 56 Issue 1 Pages 25-30
    Published: February 15, 2013
    Released on J-STAGE: February 15, 2014
    JOURNAL FREE ACCESS
    Malignant lymphoma of the nasal cavity is a relatively rare disease, and has been reported to occur more frequently in the nasal cavity than in the paranasal sinuses. Herein, we report a case of malignant lymphoma of a paranasal sinus.
    The patient was an 89-year-old male presenting with the chief complaint is an upper right toothache. He was referred to the Department of Oral and Maxillofacial of our hospital with suspected odontogenic maxillary sinusitis. The sixth upper right tooth was extracted because of purulent apical periodontitis. However, a paranasal sinus CT revealed destruction of the right maxillary sinus, and the patient was referred to our department. Since bone destruction was the only abnormal finding detected on the paranasal sinus CT and MRI, we suspected the existence of a tumor, and performed endoscopic sinus surgery and lateral rhinotomy for a definitive diagnosis. At surgery, we detected a tumor-like lesion, which was confirmed by subsequent histopathological examination to be a diffuse large B-cell lymphoma.
    A re-examination of the imaging findings revealed a number of radiographic features of malignant lymphoma with moderate bone destruction, which was also one of the features of malignant lymphoma. For malignant lymphoma of the paranasal sinuses, as in this reported case, CT of the paranasal sinuses may be useful for preoperative diagnosis.
    Download PDF (1770K)
  • Keisuke Uno, Katsutoshi Nakayama, Yoshinori Matsuwaki
    2013 Volume 56 Issue 1 Pages 31-37
    Published: February 15, 2013
    Released on J-STAGE: February 15, 2014
    JOURNAL FREE ACCESS
    Omalizumab is a monoclonal anti-IgE antibody, which is recognized as a treatment for severe asthma. We report a patient with severe asthma who showed good response of eosinophilic otitis media (EOM) and eosinophilic chronic rhinosinusitis (ECRS) to omalizumab. A 41-year-old man with severe asthma, EOM and ECRS was started on antibiotic, leukotriene antagonist, steroid nasal spray, ear-drop, and short-term systemic steroid therapy. After achieving good control of asthma, we performed endoscopic sinus surgery for ECRS. While the symptoms improved transiently just after the surgery, the symptoms of EOM recurred, and we decided to use omalizumab. After the start of omalizmab treatment, significant improvements of the symptoms of asthma, EOM as well as ECRS were observed. We tapered the systemic steroid dose in 50% decrements over 3 months, and withdrew the drug altogether 5 months after the start of omalizumab treatment. No side effects of omalizumab have been observed. This case experience suggests that omalizmab may also be effective for EOM and ECRS, presumably because of the role of IgE in both diseases.
    Download PDF (720K)
feedback
Top